Medullary Thyroid Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Medullary Thyroid Cancer - Pipeline Review, H2 2016

Medullary Thyroid Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Medullary Thyroid Cancer - Pipeline Review, H2 2016
Published Aug 17, 2016
100 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Medullary Thyroid Cancer - Pipeline Review, H2 2016, provides an overview of the Medullary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
- The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by und

  
Source:
Document ID
GMDHC8369IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Medullary Thyroid Cancer Overview81
Therapeutics Development92
  Pipeline Products for Medullary Thyroid Cancer Overview91
  Pipeline Products for Medullary Thyroid Cancer Comparative Analysis101
Medullary Thyroid Cancer Therapeutics under Development by Companies111
Medullary Thyroid Cancer Therapeutics under Investigation by Universities/Institutes121
Medullary Thyroid Cancer Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Medullary Thyroid Cancer Products under Development by Companies161
Medullary Thyroid Cancer Products under Investigation by Universities/Institutes171
Medullary Thyroid Cancer Companies Involved in Therapeutics Development1810
  AbbVie Inc181
  Advenchen Laboratories, LLC191
  Bayer AG201
  Boehringer Ingelheim GmbH211
  Celgene Corporation221
  Hutchison MediPharma Limited231
  Immunomedics, Inc.241
  Nerviano Medical Sciences S.r.l.251
  Novartis AG261
  Pfizer Inc.271
Medullary Thyroid Cancer Therapeutics Assessment2811
  Assessment by Monotherapy Products281
  Assessment by Target293
  Assessment by Mechanism of Action323
  Assessment by Route of Administration352
  Assessment by Molecule Type372
Drug Profiles3957
  AL-3818 Drug Profile393
  CLM-29 Drug Profile421
  CLM-3 Drug Profile431
  CLM-94 Drug Profile441
  everolimus Drug Profile4512
  GI-6207 Drug Profile572
  HMPL-012 Drug Profile593
  nintedanib Drug Profile6210
  NMS-616 Drug Profile721
  pasireotide Drug Profile734
  regorafenib Drug Profile7710
  rovalpituzumab tesirine Drug Profile872
  Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer Drug Profile891
  Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer Drug Profile901
  SYN-001 Drug Profile911
  temsirolimus Drug Profile922
  TF-2 Drug Profile942
Medullary Thyroid Cancer Dormant Projects961
Medullary Thyroid Cancer Discontinued Products971
Medullary Thyroid Cancer Product Development Milestones981
  Featured News &Press Releases981
    Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer981
Appendix992
  Methodology991
  Coverage991
  Secondary Research991
  Primary Research991
  Expert Panel Validation991
  Contact Us991
  Disclaimer1001

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Medullary Thyroid Cancer - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Medullary-Thyroid-Cancer-Pipeline-Review-H2-2016-2088-16395>
  
APA:
Global Markets Direct - Market Research. (2016). Medullary Thyroid Cancer - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Medullary-Thyroid-Cancer-Pipeline-Review-H2-2016-2088-16395>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.